Charles River Laboratories(CRL)

WILMINGTON, MACRO (Contract Research)16 H-1B visas (FY2023)

Focus: Charles River Laboratories is a global Contract Research Organization (CRO) with $4.1B in FY2025 revenue, providing drug development and safety testing services across the pharmaceutical and biotech industry. As a publicly traded entity, it operates at significant scale with 10,000+ employees.

Profile data last refreshed Yesterday · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Employees

10001-50000

Open Jobs

5 recent layoff filings (12 mo) — 304 affected

3/25/2026 — Wilmington, MA · 71 affected · Layoff
3/25/2026 — Wilmington, MA · 71 affected · Layoff
2/19/2026 — Wilmington, MA · 71 affected · Layoff
+2 more

Source: state DOL filings via Big Local News

About Charles River Laboratories

AI assessmentNot Hiring

No open roles listed right now. Follow Charles River Laboratories to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$4.1B

Pipeline & Clinical Trials

ETR028, ETR029, [ETR028 + ETR029] or HCBT

Acute Pain

Phase 1

[14C]-bilastine

Healthy

Phase 1

Open Jobs (0)

Help build intelligence for Charles River Laboratories

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Stable, profitable business with $4.1B revenue and $475M net income in FY2025, providing career security in a mission-critical industry function.
Exposure to the full drug development lifecycle across multiple therapeutic areas and modalities as a service provider to hundreds of pharma clients.
Strong visa sponsorship track record with 16 H1B approvals and zero denials in 2023, enabling international talent mobility.

Watch Out For

Limited proprietary pipeline (only 1 Phase 1 trial) means career growth is tied to service delivery excellence rather than transformative drug launches.
CRO model creates distance from commercial outcomes and may limit visibility into how your work impacts patient care relative to integrated pharma roles.

Generated by Claude from Charles River Laboratories's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

H-1B (2023): 16 approvals

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

Revenue

$4.1B4%

Net Income

$475M

Cash

$195M

Source: SEC 10-K Filing

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 3 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (5)

2026-03-25

71 employees affected— Wilmington, MA

source

2026-03-25

71 employees affected— Wilmington, MA

source

2026-02-19

71 employees affected— Wilmington, MA

source

2026-02-19

71 employees affected— Wilmington, MA

source

2026-02-02

20 employees affected— 3600 Cabover Drive Hanover MD 21076, MD

Source: state DOL filings, aggregated via Big Local News

No regulatory or workforce reduction signals detected in available data.